Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)
Case Comprehensive Cancer Center
Case Comprehensive Cancer Center
Ohio State University Comprehensive Cancer Center
Thomas Jefferson University
Incyte Corporation
Dana-Farber Cancer Institute
Austin Health
Innovent Biologics (Suzhou) Co. Ltd.
Washington University School of Medicine
Fate Therapeutics
University of Washington
MEI Pharma, Inc.
Brown University
SymBio Pharmaceuticals
University of Washington
Celgene
National Institutes of Health Clinical Center (CC)
Alliance for Clinical Trials in Oncology
Swiss Cancer Institute
Boehringer Ingelheim
Wake Forest University Health Sciences
UNC Lineberger Comprehensive Cancer Center
Aptevo Therapeutics
UNC Lineberger Comprehensive Cancer Center
Hoffmann-La Roche
Case Comprehensive Cancer Center
City of Hope Medical Center
CTI BioPharma
University of Alabama at Birmingham
National Cancer Institute (NCI)
Rutgers, The State University of New Jersey
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Northwestern University
National Institutes of Health Clinical Center (CC)
Mayo Clinic